BREAKING: Eli Lilly (LLY) has agreed to acquire Calytrix Bio for up to $1.5 billion in cash.
Calytrix Bio, a privately held biotech founded in 2025 by J.P. Morgan Life Sciences Private Capital, is developing precision therapies for myeloproliferative neoplasms. Its lead asset is a preclinical biparatopic antibody targeting mutant calreticulin (mCALR) in essential thrombocythemia and myelofibrosis — rare blood cancers.
The deal includes an upfront payment plus clinical and regulatory milestone payments; the upfront size was not disclosed (Reuters; Calytrix Bio announcement via PR Newswire).
#EliLilly #LLY #Biotech #Pharma #Stocks #StockMarket #FinanceNews
Calytrix Bio, a privately held biotech founded in 2025 by J.P. Morgan Life Sciences Private Capital, is developing precision therapies for myeloproliferative neoplasms. Its lead asset is a preclinical biparatopic antibody targeting mutant calreticulin (mCALR) in essential thrombocythemia and myelofibrosis — rare blood cancers.
The deal includes an upfront payment plus clinical and regulatory milestone payments; the upfront size was not disclosed (Reuters; Calytrix Bio announcement via PR Newswire).
#EliLilly #LLY #Biotech #Pharma #Stocks #StockMarket #FinanceNews
59 Views